WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 332

Legislative bill overview

SB 332 proposes to cap insulin prices in Indiana, likely limiting what consumers and insurers pay for this essential diabetes medication. The bill was introduced by Senator Mark Spencer and is currently under review by the Committee on Health and Provider Services.

Why is this important

Insulin is a life-sustaining medication for millions of Americans with diabetes, yet prices have tripled over the past two decades, forcing many patients to ration doses or skip doses due to cost. Indiana-specific price caps could reduce out-of-pocket expenses for residents, though the approach, scope, and implementation mechanism remain unclear from available information.

Potential points of contention

  • Manufacturer compliance and supply: Drug makers may reduce Indiana distribution or reformulate products to circumvent caps, potentially limiting access rather than lowering prices
  • Federal vs. state authority: Questions exist about whether Indiana can unilaterally cap insulin prices without conflicting with federal drug pricing frameworks and interstate commerce
  • Insurance market effects: Caps might shift costs to insurance premiums, deductibles, or other medications rather than reducing overall healthcare spending

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.